ICER Dumps on Wegovy Cost-Effectiveness; Kerendia Label Update; Synthetic Embryos?

The Institute for Clinical and Economic Review (ICER) said that while subcutaneous semaglutide (Wegovy) "is more effective, less burdensome, and more cost effective than liraglutide [Victoza]," it "does not meet typical cost-effectiveness thresholds at its current estimated net price."

The FDA approved a label update for finerenone (Kerendia), which treats chronic kidney disease associated with type 2 diabetes, to now include data from the phase III FIGARO-DKD and FIDELIO-DKD trials on kidney and cardiovascular outcomes, Bayer announced.

Subcutaneous insulin aspart was not only cost-effective for the treatment of kids with mild uncomplicated diabetic ketoacidosis, but was also linked with faster recovery and reduced length of hospital stay versus standard-of-care intravenous insulin infusion. (JAMA Network Open)

Of nearly 1.2 million people with type 2 diabetes living in the U.S., the prevalence of depression increased from 22% in 2006 to 29% in 2017. (Diabetologia)

Are synthetic embryos the next frontier in infertility medicine? (Nature)

In a preclinical proof-of-concept study, Adocia's investigational AdoShell Islets helped regulate glycemic control after implantation in rats with diabetes, reaching normoglycemia without insulin or immunosuppression.

Astellas Pharma announced positive findings from the 52-week phase III MOONLIGHT 3 trial of fezolinetant, an investigational oral non-hormonal vasomotor symptom treatment, adding to the 12-week phase III SKYLIGHT-2 trial findings.

Exposure to phthalates was linked with bone age advancement in a cohort of Chinese girls with early onset of puberty. (Scientific Reports)

Comment